Physician profile
Gabriel Lemus
NPI 1285821868
$6,771.94
in general payments reported to CMS, 2019-2025
22 companies · $1,529 in 2025
The $1,529 reported for 2025 was more than what 90% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,161 · 2022: $1,118 · 2023: $1,213 · 2024: $1,751 · 2025: $1,529.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,493.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,492.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $2,661.82 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $764.11 | 2021-2025 | |
| Lilly USA, LLC | $536.48 | 2021-2025 | Mounjaro, Jardiance, Emgality |
| Phathom Pharmaceuticals, INC. | $349.99 | 2024-2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $327.80 | 2021-2024 | Synjardy, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $305.53 | 2022-2025 | Xifaxan |
| Axsome Therapeutics, INC. | $245.52 | 2023-2024 | Auvelity |
| Merck Sharp & Dohme LLC | $242.58 | 2021-2022 | |
| Aimmune Therapeutics, INC. | $236.29 | 2024-2025 | Zenpep |
| Janssen Pharmaceuticals, INC | $230.75 | 2021-2022 | |
| Pfizer INC. | $165.75 | 2023-2025 | |
| Exact Sciences Corporation | $145.61 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novo Nordisk INC | $112.02 | 2022-2025 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $84.67 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amarin Pharma, INC. | $73.96 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $69.58 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $66.22 | 2021-2022 | |
| Inspire Medical Systems, INC. | $64.25 | 2024 | Inspire |
| Abbott Laboratories | $37.00 | 2023 | Freestyle Libre 3 |
| Medtronic, INC. | $22.57 | 2024 | Venaseal |
| Hikma Pharmaceuticals USA | $14.72 | 2021 | |
| Eyevance Pharmaceuticals LLC | $14.72 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gabriel Lemus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.